home
Author : adminDate : 2019-12-09 16:36

A researcher announces clinical outcome of Rivoceranib Cervical Cancer (11/15/2019)

Recently, significant clinical results have been published for cervical cancer patients using Rivoceranib in China.


 

Shandong First Medical University tested the efficacy and safety of Rivoceranib in 20 patients with cervical cancer who failed to treat cisplatin / paclitaxel ± bevacizumab (October 2019).

Jinling Hospital retrospectively tested the efficacy and safety of Rivoceranib in 6 patients with cervical cancer who failed a second or more chemotherapy (July 2019).

The First Affiliated Hospital of Wenzhou Medical University retrospectively tested the efficacy and safety of Rivoceranib in 25 patients with cervical cancer who failed a second or more chemotherapy (November 2019).


<Summary>

Subject mOS mPFS ORR DCR

1   Patients who failed primary treatment 12.3 months 5.13 months 15% 35%

2   Patients who failed secondary treatment 16 months 7 months 16.7% 67.7%

3   Patients who failed secondary treatment 12.2 months 5.8 months 48% 96%

In patients with cervical cancer who failed standard therapy, Rivoceranib showed potential as a new treatment with its high efficacy and side effects that were sufficiently manageable.


Link

https://link.springer.com/article/10.1007%2Fs10637-019-00858-5

https://www.dovepress.com/a-retrospective-six-patient-series-of-apatinib-for-the-treatment-of-pe-peer-reviewed-article-OTT

https://www.dovepress.com/clinical-value-of-apatinib-as-a-salvage-treatment-in-patients-with-che-peer-reviewed-article-OTT